Expanded Human Myeloid Cells to Support Cord Blood Transplant for Hematologic Malignancies


Clinical Trial

Offered by: Nemours
Locations: Delaware Valley, Jacksonville, FL, Orlando, FL, Pensacola, FL

Trial Name

A Phase I Trial to Determine Safety and Tolerability of Ex Vivo Expanded Human Myeloid Progenitor Cells (CLT-008) Infused 24 Hours Post-Transplant to Support Allogeneic Umbilical Cord Blood Transplantation for Hematologic Malignancies

What is the trial about?

It is believed that CLT-008 will help to promote rapid but temporary white cell recovery after cord blood transplant.

Who can participate?

Patients between ages 12-65 with certain hematologic malignancies undergoing cord blood transplant.

What is involved?

  • Patients will be followed for 100 days after receiving the CLT-008 infusion. Most study procedures will take place while your child is still an inpatient or during scheduled follow-up appointments.
  • After the CLT-008 infusion patients will be closely monitored for side effects. A total of about 13 teaspoons of extra blood will be collected over the 100-day study.

Contact Nemours Clinical Trials

Trial Name: A Phase I Trial to Determine Safety and Tolerability of Ex Vivo Expanded Human Myeloid Progenitor Cells (CLT-008) Infused 24 Hours Post-Transplant to Support Allogeneic Umbilical Cord Blood Transplantation for Hematologic Malignancies

Contact Information

(800) 354-5690
clinicaltrials@nemours.org